Integrin α9 Suppresses Hepatocellular Carcinoma Metastasis by Rho GTPase Signaling

Table 2

Correlation of clinicopathological features with ITGA9 expression in GSE14520 microarray data.

Variable		ITGA9 (n)
	High	Low	value
Age
≤50 years	51	74	0.180
>50 years	38	79
Gender
Female	12	19	0.124
Male	77	134
HBV status
AVR-CC	19	39	0.164
CC	57	103
N	2	4
ALT
>50 (U/l)	28	72	0.017
≤50 (U/l)	61	81
AFP
>300 ng/ml	49	61	0.052
≤300 ng/ml	38	90
Main tumor size
>5 cm	35	53	0.307
≤5 cm	53	100
Multinodular
No	67	123	0.351
Yes	22	30
Cirrhosis
No	7	12	0.995
Yes	82	141
TNM staging
0	11	6	0.043
I	31	65
II	25	53
III	89	29
BCLC staging
0	5	15	0.035
A	49	103
B	12	12
C	12	17
CLIP staging
0	26	72	0.016
1	28	51
2	19	16
3	4	5
4	1	2
5	0	1
Predicted risk metastasis signature
High	47	74	0.505
Low	42	79
CGH_survival_group
G1	11	8	0.063
G2	19	25

(; Pearson’s χ² test).